The FDA said more studies are needed to understand the long-term benefits and risks of bisphosphonates, a drug class used widely for osteoporosis. "These drugs clearly work," said Dr. Marcea Whitaker of the FDA's Center for Drug Evaluation and Research and a co-author of the agency's review. "We just don't know yet the optimum period of time individual patients should be on the drug to both maximize its effectiveness and minimize potential risks."

Related Summaries